Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation

被引：21

作者：

Antar, A. ^{[1
]}

Otrock, Z. K. ^{[2
]}

Kharfan-Dabaja, M. ^{[3
]}

Salem, Z. ^{[1
]}

Aractingi, S. ^{[4
,5
]}

Mohty, M. ^{[6
,7
]}

Bazarbachi, A. ^{[1
]}

机构：

[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon

[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH 44106 USA

[3] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Blood & Marrow Transplantat, Tampa, FL 33682 USA

[4] Tenon Hosp, AP HP, Dept Dermatol, Paris, France

[5] Univ Paris 06, Paris, France

[6] Univ Nantes, Hematol Clin, Nantes, France

[7] CRNCA, INSERM, UMR892, Nantes, France

来源：

BONE MARROW TRANSPLANTATION | 2013年 / 48卷 / 07期

关键词：

BONE-MARROW-TRANSPLANTATION; ACUTE-LEUKEMIA;

D O I：

10.1038/bmt.2012.256

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：994 / 995

页数：2

共 11 条

[1]

Bekassy AN, 1996, BONE MARROW TRANSPL, V17, P801

[2] Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia [J].

Berthou, C ;

Léglise, MC ;

Herry, A ;

Balcon, D ;

Hardy, E ;

Lessard, M ;

Abgrall, JF .

LEUKEMIA, 1998, 12 (11) :1676-1681

[3] Extramedullary sites of leukemia relapse after transplant [J].

Cunningham, Isabel .

LEUKEMIA & LYMPHOMA, 2006, 47 (09) :1754-1767

[4] Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome [J].

de Lima, Marcos ;

Giralt, Sergio ;

Thall, Peter F. ;

Silva, Leandro de Padua ;

Jones, Roy B. ;

Komanduri, Krishna ;

Braun, Thomas M. ;

Nguyen, Hoang Q. ;

Champlin, Richard ;

Garcia-Manero, Guillermo .

CANCER, 2010, 116 (23) :5420-5431

[5] RELAPSE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE-LEUKEMIA - A SURVEY BY THE EBMT OF 117 CASES [J].

FRASSONI, F ;

BARRETT, AJ ;

GRANENA, A ;

ERNST, P ;

GARTHON, G ;

KOLB, HJ ;

PRENTICE, HG ;

VERNANT, JP ;

ZWAAN, FE ;

GRATWOHL, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (03) :317-320

[6]

Koc Y, 1999, CANCER-AM CANCER SOC, V85, P608, DOI 10.1002/(SICI)1097-0142(19990201)85:3<608::AID-CNCR11>3.0.CO

[7]

2-5

[8] Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course [J].

Lee, KH ;

Lee, JH ;

Choi, SJ ;

Lee, JH ;

Kim, S ;

Seol, M ;

Lee, YS ;

Kim, WK ;

Seo, EJ ;

Park, CJ ;

Chi, HS ;

Lee, JS .

BONE MARROW TRANSPLANTATION, 2003, 32 (08) :835-842

[9] Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial [J].

Platzbecker, U. ;

Wermke, M. ;

Radke, J. ;

Oelschlaegel, U. ;

Seltmann, F. ;

Kiani, A. ;

Klut, I-M ;

Knoth, H. ;

Roellig, C. ;

Schetelig, J. ;

Mohr, B. ;

Graehlert, X. ;

Ehninger, G. ;

Bornhaeuser, M. ;

Thiede, C. .

LEUKEMIA, 2012, 26 (03) :381-389

[10] Management of relapse after allo-SCT for AML and the role of second transplantation [J].

Savani, B. N. ;

Mielke, S. ;

Reddy, N. ;

Goodman, S. ;

Jagasia, M. ;

Rezvani, K. .

BONE MARROW TRANSPLANTATION, 2009, 44 (12) :769-777

← 1 2 →